SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

SpringWorks Therapeutics' nirogacestat has received a positive recommendation from the European Medicine Agency’s Committee for Medicinal Products for Human Use for treating adult patients with progressing desmoid tumors requiring systemic treatment. The recommendation is based on Phase 3 DeFi trial results demonstrating a 71% reduction in disease progression compared to placebo, with improvements in patient-reported outcomes. If approved by the European Commission, a decision expected in Q3 2025, nirogacestat would be the first authorized therapy for this condition in the EU, addressing a significant unmet medical need.

Analysis

SpringWorks Therapeutics' (SWTX) nirogacestat has achieved a significant regulatory milestone with a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) for treating adult desmoid tumors, positioning it to potentially become the first EU-approved therapy for this condition. This recommendation is underpinned by robust Phase 3 DeFi trial data, where nirogacestat demonstrated a 71% lower risk of disease progression compared to placebo and improved patient-reported outcomes. The European Commission's final decision is anticipated in Q3 2025, representing a considerable waiting period for market access, although nirogacestat is already approved in the U.S. and has received Orphan Drug designation in the EU. However, this positive clinical development is contrasted by concerning market signals: insiders have executed 25 sales and zero purchases in the past six months, divesting shares worth tens of millions, including significant sales by the CEO ($7.6M) and other C-suite executives. Furthermore, data from the most recent quarter (indicated as Q1 2025 in the provided material) revealed substantial divestitures by several major hedge funds, with Deep Track Capital, Boxer Capital Management, and Ecor1 Capital liquidating their entire positions, and Maverick Capital and Capital International Investors significantly reducing theirs, collectively amounting to hundreds of millions in outflows; D.E. Shaw & Co.'s increased stake offers a notable counter-investment. Common adverse reactions associated with nirogacestat, including ovarian toxicity, may also influence future physician adoption and patient uptake. Analyst price targets for SWTX issued in the last six months show a median of $62.5, with a Barclays target of $47.0 (as of 04/28/2025) and a Guggenheim target of $78.0 (as of 01/08/2025), reflecting varied Wall Street outlooks amidst these developments.

Key Decisions for Investors

• While the positive CHMP opinion for nirogacestat in the EU is a significant de-risking event, the lengthy Q3 2025 approval timeline and substantial insider and institutional selling warrant a cautious approach to new or existing SWTX positions.
• Investors should deeply scrutinize the rationale behind the pronounced insider sales and large hedge fund divestitures, as these may indicate perceived risks or valuation concerns not fully captured by the positive clinical news.
• Monitor SpringWorks Therapeutics for progress towards final EU approval, early adoption trends for nirogacestat (particularly in the US market), the impact of reported adverse events like ovarian toxicity on market acceptance, and future institutional fund flow data before committing further capital.